In short
This article discusses the use of gebasaxturev, an investigational drug, in clinical trials for the treatment of stage III melanoma. The trials aim to evaluate the safety, efficacy, and potential benefits of gebasaxturev in combination with other treatments for patients with advanced melanoma who are candidates for neoadjuvant therapy. Understanding these trials can provide valuable insights into potential new treatment options for melanoma patients.
At a glance
- Drug Name
- Gebasaxturev (CVA21, Coxsackievirus A21)
- Trial Phase
- Phase 1/2
- Target Condition
- Stage IIIB, IIIC, or IIID melanoma
- Administration
- Intratumoral injection
- Primary Objectives
- Safety, tolerability, pathological complete response rate
- Secondary Objectives
- Near pathological complete response rate, pathological partial response rate, recurrence-free survival
- Key Inclusion Criteria
- Confirmed melanoma, untreated stage III, adequate organ function
- Key Exclusion Criteria
- Immunodeficiency, active infections, prior systemic anticancer therapy within 4 weeks
What is GEBASAXTUREV?
GEBASAXTUREV, also known as CVA21 or Coxsackievirus A21, is an investigational biological treatment being studied for advanced melanoma. It is a solution for injection that is administered directly into tumors (intratumoral use). This innovative therapy is part of a class of treatments called oncolytic viruses, which are designed to target and destroy cancer cells while sparing healthy tissue.
Medical Condition Treated
GEBASAXTUREV is being investigated for the treatment of Stage IIIB, IIIC, or IIID melanoma. Melanoma is a type of skin cancer that develops in the cells responsible for producing melanin, the pigment that gives skin its color. Stage III melanoma indicates that the cancer has spread beyond the original site to nearby lymph nodes or tissues, but has not yet reached distant parts of the body.
How GEBASAXTUREV is Used
GEBASAXTUREV is administered as a solution for injection directly into the tumor. This method, known as intratumoral injection, allows the treatment to be delivered precisely to the cancer cells. The therapy is being studied as part of a combination treatment approach, which may include other medications such as pembrolizumab, an immunotherapy drug.
Clinical Trial Objectives
The ongoing clinical trial aims to evaluate several aspects of GEBASAXTUREV treatment:
- Safety and tolerability of the treatment combination
- Effectiveness in achieving a pathological complete response (pCR), which means no detectable cancer cells remain after treatment
- Rate of near pathological complete response (near pCR) and pathological partial response (pPR)
- Impact on recurrence-free survival (RFS), or how long patients remain cancer-free after treatment
Eligibility Criteria
To participate in the clinical trial for GEBASAXTUREV, patients must meet specific criteria. Some key inclusion criteria are:
- Confirmed diagnosis of melanoma
- Stage IIIB, IIIC, or IIID melanoma that can be surgically removed
- No prior treatment for Stage III melanoma (except for surgical removal of primary melanoma or radiotherapy to the primary site)
- Adequate organ function
Exclusion criteria include:
- History of immunodeficiency or active autoimmune disease
- Recent systemic anticancer therapy or major surgery
- Known central nervous system metastases
- Ocular or mucosal melanoma
Safety Considerations
As with any investigational treatment, there are important safety considerations for patients considering GEBASAXTUREV:
- The trial monitors for adverse events (AEs) and treatment discontinuations due to AEs
- Patients with a history of pneumonitis, active tuberculosis, or certain infections are excluded from the trial
- Special precautions are taken for patients with potential exposure to live vaccines or those with a history of organ transplants
- Male and female participants must agree to use effective contraception during the treatment period and for a specified time afterward
It's important to note that GEBASAXTUREV is still under investigation, and its full safety profile and effectiveness are yet to be determined. Patients interested in this treatment should discuss their options with their healthcare provider and consider participation in clinical trials if appropriate for their situation.